Analyzing ALX Oncology (NASDAQ:ALXO) and Lumos Pharma (NASDAQ:LUMO)
Analyzing ALX Oncology (NASDAQ:ALXO) and Lumos Pharma (NASDAQ:LUMO)
ALX Oncology (NASDAQ:ALXO – Get Rating) and Lumos Pharma (NASDAQ:LUMO – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.
ALX腫瘤學(納斯達克：ALXO-GET評級)和魯莫斯醫藥(納斯達克：LUMO-GET評級)都是小盤醫療公司，但哪一家更好？我們將根據兩家公司的機構所有權、盈利能力、風險、收益、分析師建議、股息和估值等方面的實力進行比較。
Earnings & Valuation
收益與估值
This table compares ALX Oncology and Lumos Pharma's gross revenue, earnings per share and valuation.
此表比較了ALX腫瘤學和Lumos Pharma的毛收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ALX Oncology | $1.18 million | 481.02 | -$83.46 million | ($2.72) | -5.12 |
| Lumos Pharma | $230,000.00 | 307.37 | -$30.43 million | ($3.44) | -2.45 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| ALX腫瘤學 | 118萬美元 | 481.02 | -8,346萬元 | ($2.72) | -5.12 |
| 盧莫斯製藥公司 | $230,000.00 | 307.37 | -3043萬美元 | ($3.44) | -2.45 |
Lumos Pharma has lower revenue, but higher earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than Lumos Pharma, indicating that it is currently the more affordable of the two stocks.
Lumos Pharma的收入低於ALX腫瘤學，但收益高於ALX腫瘤學。ALX Oncology的市盈率低於Lumos Pharma，這表明它目前是兩隻股票中更負擔得起的一隻。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| ALX Oncology | N/A | -31.38% | -29.66% |
| Lumos Pharma | N/A | -33.81% | -29.78% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| ALX腫瘤學 | 不適用 | -31.38% | -29.66% |
| 盧莫斯製藥公司 | 不適用 | -33.81% | -29.78% |
Institutional and Insider Ownership
機構和內部人持股
89.4% of ALX Oncology shares are held by institutional investors. Comparatively, 38.4% of Lumos Pharma shares are held by institutional investors. 49.9% of ALX Oncology shares are held by insiders. Comparatively, 15.9% of Lumos Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
ALX Oncology 89.4%的股份由機構投資者持有。相比之下，Lumos Pharma 38.4%的股份由機構投資者持有。ALX Oncology 49.9%的股份由內部人士持有。相比之下，Lumos Pharma 15.9%的股份由內部人士持有。強大的機構持股表明，大型基金管理公司、捐贈基金和對衝基金相信，一家公司有望實現長期增長。
Volatility & Risk
波動性與風險
ALX Oncology has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.
ALX Oncology的貝塔係數為2.21，這表明其股價的波動性比標準普爾500指數高121%。相比之下，Lumos Pharma的貝塔係數為1.23，這表明其股價的波動性比標準普爾500指數高23%。
Analyst Recommendations
分析師建議
This is a summary of current ratings and recommmendations for ALX Oncology and Lumos Pharma, as provided by MarketBeat.
這是由MarketBeat提供的對ALX腫瘤學和Lumos Pharma的當前評級和推薦的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ALX Oncology | 0 | 1 | 6 | 0 | 2.86 |
| Lumos Pharma | 0 | 0 | 3 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| ALX腫瘤學 | 0 | 1 | 6 | 0 | 2.86 |
| 盧莫斯製藥公司 | 0 | 0 | 3 | 0 | 3.00 |
ALX Oncology currently has a consensus target price of $39.83, suggesting a potential upside of 185.95%. Lumos Pharma has a consensus target price of $24.00, suggesting a potential upside of 185.04%. Given ALX Oncology's higher possible upside, research analysts plainly believe ALX Oncology is more favorable than Lumos Pharma.
ALX Oncology目前的共識目標價為39.83美元，暗示潛在上漲185.95%。Lumos Pharma的共識目標價為24美元，暗示潛在上行185.04%。考慮到ALX腫瘤學更有可能的上行空間，研究分析師顯然認為ALX腫瘤學比Lumos Pharma更有利。
Summary
摘要
ALX Oncology beats Lumos Pharma on 10 of the 13 factors compared between the two stocks.
與Lumos Pharma相比，ALX Oncology在13個因素中有10個擊敗了Lumos Pharma。
About ALX Oncology
關於ALX腫瘤學
(Get Rating)
(獲取評級)
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
ALX Oncology Holdings Inc.是一家臨牀階段的免疫腫瘤學公司，專注於為抗癌患者開發療法。它的主要候選產品是ALX148，這是一種CD47阻斷療法，處於1b/2期臨牀試驗，用於治療骨髓增生異常綜合徵；用於治療急性髓系白血病和非霍奇金淋巴瘤，以及一系列實體腫瘤適應症，包括頭頸部鱗狀細胞癌、人表皮生長因子受體2(HER2)陽性的胃/胃食道交界癌、HER2表達的乳腺癌和其他實體腫瘤。該公司的臨牀前產品包括Alta-002，一種SIRPA TRAAC，提供對癌症的先天和適應性免疫反應的方法。ALX Oncology Holdings Inc.與默克公司簽署了一項合作協議，將對ALX148與培布羅珠單抗聯合治療頭頸部癌症的患者進行第二階段試驗；ZymeWorks公司與默克公司簽訂了一項第一階段試驗，對ALX148與HER2靶向雙特異性抗體zanidatamab在乳腺癌和其他實體腫瘤患者中的應用進行評估；Tallac Treeutics公司負責一種新型癌症免疫療法的開發、製造和商業化。它還與Selexis SA和Crystal Bioscience，Inc.簽署了許可協議。該公司成立於2015年，總部位於加利福尼亞州舊金山南部。
About Lumos Pharma
關於Lumos Pharma
(Get Rating)
(獲取評級)
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Lumos製藥公司是一家臨牀階段的生物製藥公司，專注於罕見疾病治療藥物的開發和商業化。它的主要候選治療藥物Lum-201是一種口服生長激素促分泌劑布洛莫倫，該藥正處於第二階段臨牀試驗，用於治療兒童生長激素缺乏症和其他罕見的內分泌疾病。該公司總部設在得克薩斯州奧斯汀。
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接受《ALX腫瘤學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對ALX腫瘤學和相關公司的最新新聞和分析師評級的每日簡明摘要。